All In Biotech

BLA 103770 · Swedish Orphan

Synagis

Palivizumab

NovelPriority review

Last checked: Nov 20, 2026Latest source record: May 12, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Jun 19, 1998

Approved uses

3

Original approval plus efficacy supplements

Registered trials

19

8 Phase 3, 0 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 4, 2012 Supplement 5161 · Efficacy LetterLabel
  • Sep 15, 2003 Supplement 5033 · Efficacy Review
  • Jun 19, 1998 Original approval · Type 1 - New Molecular Entity · priority review ReviewLetter
2 products under this application
  • SYNAGIS · PALIVIZUMAB 100MG/VIAL · VIAL, · Prescription
  • SYNAGIS · PALIVIZUMAB 50MG/VIAL · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Palivizumab" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 119 on PubMed

Sponsor: Swedish Orphan

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.